Catalyst Funds Management’s iRadimed IRMD Stock Holding History
Bought
Maintained
Sold
Other funds holding IRMD
NTCM
CCM
BCM
RIM
RCMC
Catalyst Funds Management's IRMD Position: Q2 2024 in Review
Catalyst Funds Management sold out of iRadimed (IRMD) in Q2 2024, closing a stake of 800 shares — an estimated $35.2K sold.
Catalyst Funds Management first reported a position in IRMD in Q1 2024 and held it in 1 quarter. The position peaked at $35.2K in Q1 2024. 138 funds tracked by Wall St. Rank hold IRMD as of Q2 2024.
- Catalyst Funds Management reported no remaining iRadimed position as of Q2 2024 after selling out during the quarter.
- Catalyst Funds Management sold 800 iRadimed shares in Q2 2024, an estimated $35.2K.
- Catalyst Funds Management first reported a position in iRadimed in Q1 2024 and held it in 1 quarter.
- Catalyst Funds Management's iRadimed position peaked at $35.2K in Q1 2024.
- 138 funds tracked by Wall St. Rank held iRadimed as of Q2 2024.
Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.